Organometallics
Article
121.5 (2C), 120.0 (2C), 74.7 (2C), 70.1 (2C), 57.3, 35.8 (2C), 31.7
̃
(6C) ppm. IR (neat): ν 3055 (w), 2959 (w), 2885 (w), 1730 (w),
357 (−54), 323 (+20), 310 (+5), 295 (+27), 245 (−46), 215 (+35),
207 (−6), 203 (+7).
1602 (w), 1580 (w), 1538 (m), 1461 (w), 1438 (w), 1413 (w), 1356
(w), 1312 (w), 1291 (w), 1279 (w), 1252 (w), 1233 (w), 1203 (w),
1154 (w), 1123 (w), 1102 (w), 1059 (w), 1039 (m), 989 (w), 959
(w), 932 (w), 888 (w), 845 (w), 809 (w), 778 (w), 750 (w), 721 (w),
695 (w), 670 (w), 647 (w), 607 (w), 585 (w), 536 (w), 459 (w)
cm−1. HRMS (APCI): m/z calcd for C53H50N4O2RhS2 [M + H]+
941.2425, found 941.2439. Mp: 167 °C (EtOAc). CD (CH2Cl2): γ,
nm (Δε, M−1 cm−1) 417 (+43), 377 (−47), 361 (−46), 332 (+80),
312 (−99), 283 (+21), 270 (+33), 248 (−33), 228 (+27), 221 (−9),
217 (+115), 207 (+30).
Synthesis of Λ- and Δ-(S,S)-Rh3. Following general procedure II,
rac-RhNS (36.9 mg, 39.3 μmol, 1.00 equiv), K2CO3 (16.3 mg, 0.12
mmol, 3.00 equiv), and BOX ligand (S,S)-2 (13.3 mg, 0.04 mmol,
1.10 equiv) were suspended in EtOH (1.60 mL, absolute) and stirred
for 2.5 h at room temperature. Purification by column chromatog-
raphy (n-pentane/EtOAc, gradient 20/1 → 15/1 → 10/1 → 7/1, plus
1% Et3N) afforded Λ-(S,S)-Rh3 (17.7 mg, 17.4 μmol, 44%) and Δ-
(S,S)-Rh3 (18.0 mg, 17.7 μmol, 45%) as yellow solids.
Λ-(S,S)-Rh3. TLC (n-pentane/EtOAc 5/1 + 1% Et3N): Rf = 0.40.
1H NMR (500 MHz, CD2Cl2): δ 8.46 (d, J = 1.6 Hz, 1H), 7.97 (d, J =
1.6 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 8.5, 1.8 Hz, 1H),
7.51 (dd, J = 8.7, 1.8 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 6.97 (dd, J =
7.1, 0.6 Hz, 1H), 6.93 (dd, J = 7.4, 1.3 Hz, 1H), 6.80−6.77 (m, 1H),
6.74−6.67 (m, 6H), 6.33 (br s, 2H), 6.26 (d, J = 7.4 Hz, 1H), 6.16 (d,
J = 7.5 Hz, 1H), 5.96 (br s, 4H), 5.75 (br s, 1H), 4.63 (dd, J = 8.7, 3.2
Hz, 1H), 4.55−4.48 (m, 3H), 4.33 (s, 1H), 3.70 (dd, J = 8.1, 3.2 Hz,
1H), 3.63 (s, 3H), 3.61 (dd, J = 7.4, 2.3 Hz, 1H), 2.19−2.13 (m, 9H),
1.90−1.84 (m, 6H), 1.52 (s, 9H) ppm. 13C NMR (126 MHz,
CD2Cl2): δ 176.3 (d, JC,Rh = 3.5 Hz, 1C), 174.3 (d, JC,Rh = 30 Hz, 1C),
173.8 (d, JC,Rh = 29 Hz, 1C), 170.0, 169.8, 158.9 (d, JC,Rh = 3.1 Hz,
1C), 152.3, 151.7, 147.3, 146.2, 145.4, 142.3, 141.0, 136.6, 134.2,
133.6, 133.1, 129.9, 129.4, 128.5, 127.2 (2C), 126.8 (2C), 126.5
(2C), 126.1, 125.6 (2C), 125.3, 125.1, 123.9, 122.5, 121.6, 121.5,
121.3, 120.9, 118.8, 114.4, 108.7, 74.8, 74.7, 70.2, 70.1, 53.0, 43.8
(3C), 37.1 (3C), 37.1, 35.4, 32.2 (3C), 31.9, 29.6 (3C) ppm. IR
General Procedure III: Acid-Induced Removal of Coordi-
nated Auxiliary Ligand. To a solution of Λ- or Δ-(S,S)-2/3 (1.00
equiv) in MeCN (0.04 M) was added methanesulfonic acid (10.0
equiv) in one portion at 0 °C. After 15 min, the ice bath was removed
and the solution was stirred for a further 6 h at room temperature.
Alternatively, the reaction mixture may be stirred for 16 h without
affecting the ee value of the final catalyst. The solvent was removed
under reduced pressure (250−50 mbar for a maximum of 10 min),
NH4PF6 (15.0 equiv) was added to the residual yellow oil, and MeCN
(0.02 M) was added. The resulting suspension was stirred for 30 min
at room temperature before the solvent was removed under reduced
pressure. Purification by column chromatography (CH2Cl2/MeCN
20/1) provided the enantiomerically pure rhodium(III) complexes.
Synthesis of Λ-RhS. Following general procedure III with Λ-(S,S)-
Rh2 (20.0 mg, 21.3 μmol, 1.00 equiv), Λ-RhS (18.0 mg, 20.9 μmol,
98%) was obtained as a pale yellow solid after column chromato-
graphic purification. The enantiomeric excess was established by
HPLC analysis using a Daicel Chiralpak IB-N5 column, ee >99.9%
(HPLC: 254 nm, H2O + 0.1% TFA/MeCN 40−50% MeCN in 180
min, 50% MeCN maintained for a further 60 min, flow rate 0.6 mL/
min, 25 °C, tR(Δ-RhS) = 210.0 min, tR(Λ-RhS) = 217.8 min).
Analytical data were in agreement with the literature.9 1H NMR (300
MHz, CD2Cl2): δ 8.50 (br s, 2H), 8.02 (d, J = 8.6 Hz, 2H), 7.72 (dd,
J = 8.6, 1.7 Hz, 2H), 7.67 (dd, J = 7.6, 1.2 Hz, 2H), 7.03 (dt, J = 7.5,
0.8 Hz, 2H), 6.83 (dt, J = 7.6, 1.4 Hz, 2H), 6.21 (d, J = 7.8 Hz, 2H),
2.18 (br s, 6H), 1.46 (s, 18H) ppm.
Synthesis of Δ-RhS. Following general procedure III with Δ-(S,S)-
Rh2 (22.0 mg, 23.4 μmol, 1.00 equiv), Δ-RhS (19.9 mg, 23.1 μmol,
99%) was obtained as a pale yellow solid after purification by column
chromatography. The enantiomeric excess was established by HPLC
analysis using a Daicel Chiralpak IB-N5 column, ee >99% (HPLC:
254 nm, H2O + 0.1% TFA/MeCN 40−50% MeCN in 180 min, 50%
MeCN maintained for a further 60 min, flow rate 0.6 mL/min, 25 °C,
tR(Δ-RhS) = 210.0 min, tR(Λ-RhS) = 217.8 min). Analytical data
were in agreement with the literature.9 1H NMR (300 MHz, CD2Cl2):
δ 8.48 (d, J = 1.5 Hz, 2H), 8.03 (d, J = 8.6 Hz, 2H), 7.72 (dd, J = 8.6,
1.8 Hz, 2H), 7.67 (dd, J = 7.6, 1.2 Hz, 2H), 7.03 (dt, J = 7.5, 0.9 Hz,
2H), 6.83 (dt, J = 7.6, 1.3 Hz, 2H), 6.20 (d, J = 7.8 Hz, 2H), 2.17 (br
s, 6H), 1.46 (s, 18H) ppm.
Synthesis of Λ-RhNS. Following general procedure III with Λ-
(S,S)-Rh3 (20.0 mg, 19.7 μmol, 1.00 equiv), Λ-RhNS (17.5 mg, 18.7
μmol, 95%) was obtained as a pale yellow solid after column
chromatographic purification. Since the enantiomeric excess could not
be established by chiral HPLC, Λ-RhNS was reconverted into Λ-
(S,S)-Rh3 and a dr value of >20:1 was determined by 1H NMR of the
(CH3OH): λ, nm (Δε, M−1 cm−1) 389 (−29), 355 (+88), 298 (−95),
244 (+65), 228 (+14), 220 (+26), 214 (−17), 206 (+66). All other
analytical data were in agreement with rac-RhNS (see the Supporting
Synthesis of Δ-RhNS. Following general procedure III with Δ-
(S,S)-Rh3 (30.0 mg, 29.5 μmol, 1.00 equiv), Δ-RhNS (26.2 mg, 27.9
mmol, 95%) was obtained as a pale yellow solid after purification by
column chromatography. Since the enantiomeric excess could not be
established by chiral HPLC, Δ-RhNS was reconverted into Δ-(S,S)-
Rh3 and a dr value of >20:1 was determined by 1H NMR of the crude
(Δε, M−1 cm−1) 389 (+30), 355 (−91), 298 (+101), 244 (−65), 228
(−18), 220 (−29), 214 (+10), 206 (−67). All other analytical data
(neat): ν 2900 (m), 2848 (w), 1612 (w), 1580 (w), 1531 (w), 1476
̃
(w), 1451 (w), 1414 (w), 1347 (w), 1322 (w), 1288 (w), 1260 (w),
1207 (w), 1111 (w), 1064 (w), 1034 (w), 992 (w), 962 (w), 933 (w),
867 (w), 797 (w), 758 (w), 724 (w), 696 (w), 668 (w), 637 (w), 615
(w), 542 (w), 460 (w) cm−1. HRMS (APCI): m/z calcd for
C60H59N5O2RhS [M + H]+ 1016.3439, found 1016.3464. Mp: 141 °C
dec (EtOAc). CD (CH3OH): γ, nm (Δε, M−1 cm−1) 388 (−13), 353
(+60), 299 (−42), 269 (+29), 260 (+25), 245 (+57), 216 (−69), 202
(−18).
Δ-(S,S)-Rh3. TLC (n-pentane/EtOAc 5/1 + 1% Et3N): Rf = 0.27.
1H NMR (500 MHz, CD2Cl2): δ 9.05 (d, J = 1.5 Hz, 1H), 8.54 (d, J =
1.4 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.59 (dd, J = 8.6, 1.7 Hz, 1H),
7.56 (dd, J = 8.7, 1.7 Hz, 1H), 7.47 (d, J = 8.7 Hz, 1H), 7.42 (d, J =
7.7 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 6.76−6.72 (m, 4H), 6.69 (d, J
= 7.3 Hz, 2H), 6.62−6.57 (m, 4H), 6.47−6.42 (m, 2H), 5.90−5.83
(m, 2H), 5.57 (d, J = 7.8 Hz, 1H), 5.41 (d, J = 7.8 Hz, 1H), 4.37 (s,
1H), 4.17 (s, 3H), 4.07−4.03 (m, 2H), 3.71 (m, 2H), 3.57 (dd, J =
9.9, 8.3 Hz, 1H), 3.43 (dd, J = 11.3, 8.3 Hz, 1H), 2.22−2.16 (m, 6H),
2.12 (m, 3H), 1.82 (m, 6H), 1.53 (s, 9H) ppm. 13C NMR (126 MHz,
CD2Cl2): δ 176.2 (d, JC,Rh = 3.1 Hz, 1C), 175.1 (d, JC,Rh = 31.0 Hz,
1C), 173.8 (d, JC,Rh = 30.3 Hz, 1C), 171.7, 171.2, 160.0 (d, JC,Rh = 3.7
Hz, 1C), 152.0, 151.1, 146.6, 144.4, 143.8, 140.9, 139.8, 135.2, 134.3,
134.1, 133.8, 129.1, 128.5, 127.6 (4C), 127.5, 127.3 (2C), 127.3
(2C), 125.9, 125.8, 124.6, 123.1, 122.9, 121.8, 121.3, 121.0, 120.8,
120.4, 116.1, 108.9, 74.9, 74.5, 70.1, 69.9, 56.5, 43.6 (3C), 37.4, 37.2
(3C), 35.5, 32.4, 32.0 (3C), 29.6 (3C) ppm. IR (neat): ν 2899 (m),
̃
2847 (w), 1603 (w), 1581 (w), 1534 (w), 1504 (w), 1475 (w), 1458
(w), 1437 (w), 1415 (w), 1353 (w), 1310 (w), 1289 (w), 1256 (w),
1232 (w), 1209 (w), 1149 (w), 1103 (w), 1062 (w), 1034 (w), 989
(w), 960 (w), 865 (w), 799 (w), 751 (w), 723 (w), 695 (w), 668 (w),
650 (w), 609 (w), 536 (w), 459 (w) cm−1. HRMS (APCI): m/z calcd
for C60H59N5O2RhS [M + H]+ 1016.3439, found 1016.3468. Mp: 181
°C dec (EtOAc). CD (CH3OH): γ, nm (Δε, M−1 cm−1) 393 (+19),
ASSOCIATED CONTENT
■
S
* Supporting Information
The Supporting Information is available free of charge on the
F
Organometallics XXXX, XXX, XXX−XXX